Back to Attorneys

David Lancaster

Partner
Quick Actions
Offices }
Lancaster, David
Lancaster, David
David Lancaster
davidlancaster@quinnemanuel.com
Biography Recent News Practices Representations

David Lancaster is a partner and Head of Intellectual Property Litigation in Quinn Emanuel’s London Office.

David specialises in the litigation and resolution of disputes relating to intellectual property rights, including patents, trade marks, copyright, designs and confidential information. David is highly experienced in representing clients in litigation before the English Courts and co-ordinating proceedings before European national courts and the European Patent Office. David is qualified as a barrister in both England & Wales and Ireland and advises clients in relation to the Unified Patent Court.

David has a technical background in biochemistry and acts for clients across a range of business sectors, including life sciences, telecommunications (including FRAND licensing), computing, financial services, energy and manufacturing.

‘David Lancaster is a great lawyer who uses his scientific knowledge to excellent effect.’ – Legal 500, 2022

Quinn Emanuel recognised as a ‘Firm to Watch’ in the UK for Intellectual property: patents (contentious and non-contentious) – Legal 500, 2025

Practice Areas

Notable Representations

Public cases include:

  • Representing Bioeq and Teva in patent infringement and validity proceedings against Novartis relating to pre-filled syringes of biosimilar ranibizumab
  • Representing East Anglia One in patent infringement and validity proceedings relating to offshore wind turbine construction
  • Representing Archos in patent infringement, validity and FRAND proceedings against Sisvel and Mitsubishi relating to 3G/4G tablet devices
  • Representing Accord in patent validity proceedings against Allergan relating to a formulation of bimatoprost
  • Representing Biogen (with Samsung Bioepis) in patent litigation and declaratory proceedings against AbbVie relating to dosing regimens for biosimilar adalimumab
  • Representing Human Genome Sciences in patent and SPC litigation against Eli Lilly relating to an antibody treatment for lupus
  • Representing Vringo in patent infringement, validity and FRAND proceedings against ZTE relating to 3G/4G base stations for mobile telecommunications
  • Representing the Icahn School of Medicine at Mount Sinai in obtaining SPC protection before the UK Intellectual Property Office and against Genzyme before the Opposition Division of the European Patent Office relating to agalsidase beta treatment for Fabry disease
  • Representing Rovi in patent infringement and validity proceedings against Virgin Media relating to electronic programme guides for satellite television
  • Representing KHS Corpoplast and Norgren in patent litigation against Eugen Seitz relating to pneumatic components used in the manufacture of PET plastic bottles
  • Representing GlaxoSmithKline Biologicals in patent litigation against Novartis relating to the manufacture of meningococcal vaccines

David has advised clients in connection with potential patent litigation across a range of business sectors, including computing (multi-factor authentication), financial services (electronic payment methods), transport (electric vehicles, airline seats), energy (offshore wind, nuclear power), medical devices (syringes, medical imaging), life sciences (pharmaceuticals, antibodies, vaccines, cell & gene therapies), manufacturing (construction, plastic manufacture, cleaning agents).

Education

  • Merton College, University of Oxford
    (MBiochem, Biochemistry, 1st Class Honours, 2003)
  • Linacre College, University of Oxford
    (DPhil, Biological Chemistry, 2006)
  • City University, London
    (CPE, Law, 2007; BVC, Law, 2008)
  • Diploma in Intellectual Property Law and Practice, University of Oxford
    (2014)

Admissions

  • Barrister, England & Wales
  • Barrister, Ireland

Prior Associations

  • Pinsent Masons LLP:
    • Partner, 2020-2023
    • Legal Director, 2019-2020
  • Powell Gilbert LLP:
    • Associate and Senior Associate, 2012-2019
  • Rouse Legal:
    • Associate, 2009-2012
  • Three New Square:
    • Pupil Barrister, 2008-2009

Awards

  • Recommended by Managing IP: IP STARS, Notable Practitioner, 2024
  • Recommended by Who’s Who Legal as a Global Leader in Patents since 2022
  • Recommended by Who's Who Legal as a Global Leader in Life Sciences Patent Litigation since 2016
  • Lord Mansfield Scholar (Lincoln’s Inn, 2008)

Accolades include:

  • ‘David Lancaster is a great lawyer who uses his scientific knowledge to excellent effect.’ – Legal 500, 2022
  • ‘David Lancaster has strong experience in the life sciences sector and has built a respected practice as a patent litigator.’ – Who’s Who Legal, 2017

Publications and Lectures

Recent publications include:

  • “How to exploit the UPC opt out” – Managing IP, September 2022
  • “The Evolving Biosimilar Approach” – Biopharm International Regulatory Sourcebook, October 2021
  • Quoted in “Ruling on Cellular Standards Patents Scrambles Global Enforcement Landscape” by Michael Rosen, American Enterprise Institute, September 2020

Professional Activities

  • Member, AIPPI UK
  • Associate Member, Chartered Institute of Patent Attorneys